Amlodipino

Quick links to important sections

Amlodipino

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlodipino

Property Description
Active ingredient Amlodipine (typically as the besylate salt)
Form Tablets, Oral solution, Oral suspension
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
General purpose Manage high blood pressure and relieve angina
Origin Synthetic

What Type of Medicine is Amlodipino?

Amlodipino is a synthetic pharmaceutical agent whose active compound is Amlodipine, which is often administered as the salt Amlodipine besylate. The compound is scientifically classified as a Calcium Channel Blocker, specifically belonging to the Dihydropyridine group. This classification strictly defines its function in cardiovascular therapy. Research confirms Amlodipine is clinically recognized for providing stable, long-term cardiovascular management.

This medication is a prescription-only drug characterized by its long-acting molecular structure, which allows it to sustain a consistent therapeutic effect. Its general importance is validated by its inclusion on the World Health Organization (WHO) list of essential medicines.

Composition and Available Forms of Amlodipine

The composition is centered on the Amlodipine besylate active ingredient, combined with pharmaceutical excipients necessary for stable oral delivery. While Amlodipine is widely available in numerous generic formulations, it is predominantly used as a single-agent formulation.

The drug is available in various oral dosage forms, including traditional solid tablets and specialized liquid formats such as oral solution or oral suspension for administration via the oral route. The availability of these forms helps accommodate diverse patient groups and is a key feature of its formulation structure.

What is Amlodipine Generally Used For?

The general purpose of Amlodipino is to promote peripheral arterial vasodilation—the relaxation and widening of the small arteries—thereby significantly reducing the resistance within the vascular system. This mechanism of lowering the pressure faced by the heart is the fundamental principle used to manage high blood pressure, known as hypertension.

As an effective slow-channel blocker, Amlodipino helps ensure proper blood and oxygen delivery to the heart muscle. This action is the general principle applied for the relief of chest discomfort associated with angina, enabling consistent pressure management through selective vascular targeting.

Regulatory References

  1. WHO Essential Medicines List for Amlodipine

What side effects are possible with Amlodipino?

Possible Side Effects and Safety Information

The safety profile for Amlodipino is based on clinical trials and post-marketing surveillance, with adverse reactions categorized by their documented frequency.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Very Common (Affects ge 1 in 10) Oedema (swelling, typically peripheral/ankle swelling).
Common (Affects ge 1 in 100) Headache, dizziness, somnolence, palpitations, flushing, abdominal pain, nausea, fatigue, asthenia, muscle cramps.
Uncommon Insomnia, mood changes, tremor, syncope, hypotension, rhinitis, vomiting, dry mouth, alopecia, rash, pruritus, arthralgia, myalgia.
Very Rare (Affects < 1 in 10,000) Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, myocardial infarction, hepatitis, pancreatitis, severe skin reactions (e.g., Stevens-Johnson syndrome).

Serious Adverse Reactions

Documented serious adverse reactions are rare but include myocardial infarction, hepatitis, and severe skin conditions such as Stevens-Johnson syndrome and angioedema. These events are classified as Very Rare in regulatory documents.

Population-Specific Safety Considerations

Official regulatory documents note that clearance of Amlodipino is decreased in older adults and patients with hepatic (liver) impairment. A lower initial dose may be appropriate in these groups due to the potential for increased drug exposure. The safety and effectiveness of Amlodipino use in pediatric patients under 6 years old have not been established.

Safety-Related Restrictions

Use of Amlodipino is restricted in patients with specific cardiovascular conditions, including known hypersensitivity, severe hypotension, cardiogenic shock, obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis), and haemodynamically unstable heart failure after acute myocardial infarction. Caution is advised in patients with severe aortic stenosis.

Overdose and Emergency Response

Overdose with Amlodipino is documented in regulatory sources as potentially resulting in a state of excessive peripheral vasodilation. This physiological change leads to marked hypotension, which is a critical clinical sign. In some cases, a reflex tachycardia may also be observed. Because of the risk of profound systemic hypotension and the potential for cardiovascular collapse, individuals must seek medical help right away or contact emergency services if an overdose is suspected.

Governmental authorities mandate that in cases of massive overdose, professionals must initiate active cardiac and respiratory monitoring. Management requires intensive cardiovascular support, including essential measures such as elevation of the extremities and judicious administration of fluids. If hypotension remains unresponsive to these conservative steps, the use of vasopressors may be considered. Continuous monitoring of blood pressure and urine output is required.

Extended observation is typically necessary due to the compound’s long half-life, which may necessitate an overnight hospital stay. It is officially stated that no specific antidote is known for Amlodipino. Furthermore, due to the drug’s high protein binding, procedures like hemodialysis are not expected to be of benefit in increasing its elimination.

Therapeutic Uses of Amlodipino

What Amlodipine Treats: Main Uses and Benefits

Amlodipine is commonly used to assist with the management of conditions related to the heart and blood vessels, including chronic high blood pressure (hypertension) and certain types of chest pain (angina). The medication is relevant for easing high blood pressure and angina or coronary artery disease.

Therapeutic Scope and Benefits

Amlodipine is applied across domains where additional symptomatic support is needed for symptoms related to systemic imbalance, specifically the persistent high pressure in the arteries, and for symptom clusters that may become intense or disruptive related to angina. This therapy is primarily relevant in conditions characterized by periods of heightened symptoms, such as chronic hypertension and recurrent episodes of chest discomfort.

The patient-oriented benefit is that the medication provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases. For patients experiencing angina, Amlodipine helps manage the intensity and occurrence of episodes of discomfort, which assists with maintaining functional stability.


Quick Fact: Supportive Management for Symptoms Amlodipine is generally used in conditions presenting with systemic or localized discomfort and heightened physiological activity.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Amlodipino's use is strictly defined by government regulatory documents, outlining populations for whom it is permitted, contraindicated, or restricted.

Eligibility Scope

Category Status
Populations for whom use is allowed Adults; Children and adolescents with hypertension, aged 6 to 17 years
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or dihydropyridine derivatives; Severe hypotension; Shock (including cardiogenic shock); Obstruction of the left ventricular outflow tract (e.g., high grade aortic stenosis); Haemodynamically unstable heart failure after acute myocardial infarction

Eligibility Restrictions

  • Children under 6 years: Safety and efficacy are not established.
  • Hepatic Impairment: Use requires caution. Dosage selection must be cautious and initiated at the lower end of the dosing range.
  • Renal Impairment: No dosage adjustment is required.
  • Pregnancy and Lactation: Safety has not been established in human pregnancy; use is restricted to cases where the benefit justifies the risk. The drug passes into breast milk, and use is generally not recommended during lactation.

What should I know about interactions with other medicines?

Amlodipino's interaction profile is primarily defined by its metabolic pathway and the risk of additive effects with co-administered medicinal products and substances.

Pharmacokinetic Interactions

Amlodipine undergoes extensive metabolism mediated by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with strong or moderate CYP3A4 inhibitors (e.g., Itraconazole, Clarithromycin) is officially documented to increase Amlodipine’s systemic exposure (AUC). Conversely, co-administration with CYP3A4 inducers (e.g., Rifampicin, St John’s Wort) may decrease Amlodipine plasma concentrations, which is a consideration for blood pressure monitoring. The effects of CYP3A4 inhibitors may be more pronounced in patients with hepatic impairment, as they already exhibit decreased clearance and increased exposure.

Interaction-Related Restrictions

A key regulatory constraint involves co-administration with Simvastatin. Regulatory labeling requires the dose of Simvastatin to be limited to a maximum of 20 mg daily due to Amlodipine causing a significant increase in Simvastatin exposure. Furthermore, Amlodipine can increase the blood levels of immunosuppressants such as Tacrolimus and Ciclosporin; monitoring of the immunosuppressant agent is required in these cases.

Pharmacodynamic Effects and Substance Interactions

Pharmacodynamic interactions include additive blood pressure-lowering effects when combined with other antihypertensive agents or PDE5 inhibitors (e.g., Sildenafil), which increases the risk of hypotension. Regarding non-medicinal substances, consumption of Grapefruit or grapefruit juice is officially noted as not recommended, as it may increase Amlodipine's bioavailability in some individuals.

Mechanism of Action

Selective Blockade of Vascular L-Type Calcium Channels

Amlodipino exerts its primary effect by acting as a selective antagonist of the Voltage-dependent L-type Calcium Channels (CaV1) located on the membranes of vascular smooth muscle cells. The drug’s slow kinetics of association and dissociation from the receptor site facilitate its prolonged functional duration. By occupying the channel, Amlodipino mechanically blocks the influx of extracellular calcium ions ( Ca^2+), which are essential signals for muscle contraction.


️ Causal Cascade for Peripheral Arterial Vasodilation

The blockage of calcium entry interrupts the fundamental Myosin Light-Chain Kinase ( MLCK) cascade, reducing the capacity of smooth muscle for contraction. This leads to the sustained relaxation and widening of the peripheral arteries and arterioles (vasodilation). This physiological change, by reducing the overall resistance in the circulatory system, results in a reduction of the mechanical load, or Afterload, on the heart.


Modulation of Systemic Hemodynamic Resistance

The widespread peripheral vasodilation mechanically decreases the Total Peripheral Resistance ( TPR), which is the primary systemic consequence of the drug's action. This modulation is defined by the consequent decrease in pressure the heart must overcome to eject blood, which mechanically lowers the myocardial oxygen demand. A secondary but related mechanism is the ability to directly oppose coronary artery spasm, which influences blood flow regulation within the heart's own circulation.

Dosage and Administration Information

Instruction Map: How to use Amlodipino — Administration Guidelines

The usage of Amlodipino is defined by guidelines concerning the route, dose, frequency, and conditions of administration.

Entity Specification
Route of administration Administration is exclusively oral (via ingestion).
Dosing schedule (Adults) The typical initial dose is 5 mg once daily, and the maximum daily dose is 10 mg.
Timing in relation to meals Amlodipine tablets may be taken with or without food.
Age-group administration rules A lower starting dose of 2.5 mg once daily is specified for older adults and patients with hepatic impairment. Pediatric patients (6–17 years) for hypertension start at 2.5 mg once daily.
Missed-dose rules If a scheduled daily dose is missed, it should be taken as soon as possible on the same day. If it is already near the time for the next dose, the missed dose must be skipped, and the regular schedule resumed.
Special procedural conditions Dose adjustments are subject to a 7-to-14-day interval or longer before any increase is made, following guidelines for titration.

Instruction Classifications (High-Level)

Classification Specification
Administration method type Oral
Frequency pattern Once daily
Guideline basis Standardized across clinical guidelines
Use-context constraints Specific populations (e.g., older adults) require a defined lower initial dose.

Connection to the overall use protocol

The instructions establish a standardized, long-term administration protocol centered on a simple, once-daily oral intake that is independent of mealtimes. This structure is governed by a published dosing range and a required titration interval of at least one to two weeks, ensuring that any dose changes follow a slow, measured, and standardized schedule as prescribed by healthcare authorities.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amlodipino

Evidence for Use in Chronic High Blood Pressure (Hypertension)

Research exploring Amlodipino in the context of high blood pressure has been extensive, primarily involving large-scale, long-term Randomized Controlled Trials (RCTs). These studies involved Adults with primary hypertension, as well as high-risk groups, including those with diabetes mellitus and certain types of chronic kidney disease. Research primarily tracked changes in blood pressure (BP) measurements, alongside the incidence of major long-term Cardiovascular Events, such as stroke and myocardial infarction, and all-cause mortality.

The findings from this research describe patterns related to changes in blood pressure when Amlodipino was studied for hypertension management. The data show patterns related to the incidence of serious cardiovascular events in observed populations. However, subgroup findings are uncertain in some lower-risk populations, and research is ongoing to further refine its specific utility across all potential patient subgroups.


Evidence for Use in Chronic Stable Angina

Amlodipino was evaluated in trials focused on managing chronic stable chest discomfort. These studies examined outcomes related to physical discomfort and daily functioning. Specifically, research monitored patient-reported outcomes describing perceived discomfort, such as the frequency of anginal episodes, and the use of short-acting nitrates.

Trial results report how symptoms evolved in the observed populations, with findings describing patterns where the frequency of episodes was observed to change over the short-term study period. Evidence contributes to understanding symptom patterns, but long-term effects on major cardiovascular events are not fully established, as follow-up durations were limited in many of the symptom-focused trials.


Evidence for Vasospastic Angina

Research has explored Amlodipino was studied for conditions characterized by fluctuating or episodic manifestations, specifically vasospastic (Prinzmetal's) angina. These studies examined outcomes describing episodic or acute changes, primarily focusing on the frequency of sudden episodes of chest pain in Adults with the confirmed condition.

Sample sizes for the controlled trials for this condition are more modest compared to the evidence base for chronic stable angina or hypertension. Therefore, the evidence concerning long-term outcomes, such as the overall impact on the prognosis or the prevention of severe cardiac events in this specific population, is not fully established.


What Is Still Uncertain About Amlodipino Research

While the overall evidence landscape is comprehensive, particularly for adult hypertension, research is not exhaustive. Comparative evidence is lacking for Amlodipino against certain newer anti-hypertensive drugs in head-to-head trials powered for long-term cardiovascular outcomes. Furthermore, data for certain groups remain insufficient, including evidence for long-term use in pediatric patients with hypertension. Long-term effects in some highly specific subgroups are not fully established. Research helps show what has been observed so far in large groups, but research does not determine whether an individual will respond similarly to the patterns described.

Frequently Asked Questions (FAQ)

Common questions about Amlodipino (FAQ)


Q: How quickly should I expect Amlodipino to start lowering my blood pressure?

Official product information indicates that the blood pressure lowering effect of Amlodipino is gradual. The reduction in blood pressure typically begins to occur 4 to 8 hours after a single dose is taken.


Q: What is the typical timeframe for seeing the maximum effect of Amlodipino?

According to official regulatory information, the maximum concentration of the drug in the bloodstream is reached 6 to 12 hours after an oral dose. This time frame indicates when the concentration of the drug is highest in the bloodstream.


Q: Does taking Amlodipino prevent heart attacks or strokes?

Official prescribing information indicates that lowering blood pressure is associated with a reduced risk of serious cardiovascular events, including fatal and nonfatal strokes and myocardial infarctions (heart attacks). Amlodipino is part of a management plan intended to help achieve this goal.


Q: Is Amlodipino considered a blood thinner?

Amlodipino is chemically classified as a Calcium Channel Blocker and functions by widening blood vessels. It is not primarily identified as a blood thinner (an anticoagulant or antiplatelet medicine) in regulatory or product information.


Q: Do you have to take Amlodipino at the same time every day?

Official administration guidelines state that the medicine should be taken at the same time each day. This helps maintain consistent drug levels in the body, which is important for management.


Q: What is the average duration of treatment with Amlodipino?

Treatment with Amlodipino is typically considered to be long-term. It is not intended for short-term use, but rather for the ongoing management of chronic conditions like high blood pressure and angina.


Q: Can I stop taking Amlodipino if my blood pressure returns to normal?

Regulatory and patient information suggests that stopping this type of treatment, especially if done abruptly, can increase the risk of your blood pressure rising again. Changes to treatment, including discontinuation, are typically managed under the supervision of a healthcare provider.


Q: Can Amlodipino be crushed or split if it's difficult to swallow?

Official patient information notes that the 5 mg and 10 mg tablets can be divided into equal doses. This is noted in patient information to allow for appropriate dose administration when a lower strength is prescribed.


Q: Will Amlodipino affect my ability to drive or operate machinery?

Official product labeling indicates that Amlodipine can have a minor to moderate influence on the ability to drive. If dizziness, headache, fatigue, or nausea are experienced, official product labeling indicates the capacity to react may be impaired.


Q: Is it normal to feel dizzy when first starting Amlodipino?

Yes, dizziness and sleepiness are listed as common side effects of the medication. These effects are often more noticeable when treatment is first initiated.


Q: Can Amlodipino cause fatigue or tiredness?

Yes, official product information lists both fatigue and asthenia (a general lack of energy or weakness) as common side effects of Amlodipino.


Q: Does Amlodipino cause weight gain?

According to regulatory side effect listings, both weight increase or decrease are documented as a rare side effect, meaning it affects less than 1 in 100 people.


Q: Can Amlodipino cause problems with sleep or insomnia?

Official safety information lists insomnia (difficulty sleeping) as an uncommon side effect of the drug.


Q: Does Amlodipino have any effect on sexual function?

Official product information lists erectile dysfunction as an uncommon side effect.


Q: What are the signs of a serious allergic reaction to Amlodipino?

Serious allergic reactions are rare but documented in official sources. Signs may include severe skin reactions (like Stevens-Johnson syndrome) and swelling of the face, lips, or tongue (angioedema).


Q: Does Amlodipino affect liver function?

Clearance of the drug is decreased in patients with pre-existing hepatic (liver) impairment, requiring caution in those populations. Additionally, hepatitis is listed as a very rare side effect.


Q: Can Amlodipino affect blood sugar levels in diabetic patients?

Regulatory documents list hyperglycaemia (excess sugar in the blood) as a very rare side effect of the medication.


Q: Does Amlodipino interact with alcohol?

Yes, official information indicates that alcohol may have additive effects with Amlodipino in lowering blood pressure. This combination can increase the risk of symptoms like dizziness or fainting.


Q: Does Amlodipino interact with grapefruit or grapefruit juice?

Consumption of grapefruit or grapefruit juice is not recommended. This is because it may increase the concentration of Amlodipino in the bloodstream, potentially leading to a greater drop in blood pressure.


Q: What common foods, besides grapefruit, should be avoided with Amlodipino?

According to patient-facing regulatory information, there are no other common foods explicitly restricted or required to be avoided when taking Amlodipino, apart from grapefruit.


Q: Are there any known drug interactions between Amlodipino and popular herbal remedies?

Yes, the herbal remedy St John’s Wort is specifically noted in regulatory drug interaction summaries as potentially affecting the way Amlodipino works in the body.


Q: Does Amlodipino interact with any common supplements like potassium or magnesium?

Regulatory sources advise that the use of Amlodipine together with multivitamins that contain minerals is noted to potentially decrease the effects of Amlodipine.


Q: Is there a generic version of Amlodipino available?

Yes, the active compound Amlodipine (typically administered as the besylate salt) is widely available in generic formulations.


Q: What's the difference between Amlodipino and Amlodipino besylate?

Amlodipino besylate is the specific salt form of the active drug Amlodipine that is typically contained in the tablets. The use of a salt form ensures stability and proper absorption of the medication.


Q: How long does Amlodipino stay in your system?

The time it takes for the drug concentration to drop by half in the body (its terminal half-life) is about 30 to 50 hours. This long half-life is the pharmacological basis for once-daily dosing.


Q: Is Amlodipino safe for people who have had a heart attack?

Official warnings state that use is restricted (contraindicated) in patients who have haemodynamically unstable heart failure after an acute myocardial infarction (heart attack).


Q: Is Amlodipino safe for women who are planning a pregnancy?

The safety of the drug in human pregnancy has not been fully established. Therefore, official information indicates that individuals planning to become pregnant should inform their healthcare provider.


Q: Is Amlodipino used for treating all types of hypertension?

Amlodipino is indicated for the treatment of hypertension (high blood pressure) and chronic stable angina. The professional labeling does not specify its use for all or specific types of primary hypertension, but for hypertension generally.


Q: What are the most common long-term side effects of Amlodipino?

Regulatory documents list side effects by frequency (e.g., Very Common, Common) but do not explicitly distinguish between short-term and long-term effects. The most frequently reported side effects include headache and peripheral edema (swelling of the ankles or feet).


Q: Why is Amlodipino sometimes prescribed with other blood pressure medicines?

The drug is often combined with other anti-hypertensives because it can provide additive effects in lowering blood pressure. This combination approach may be necessary to achieve or maintain optimal blood pressure targets.


Q: What is the average duration of treatment with Amlodipino?

Treatment with Amlodipino is typically considered to be long-term. It is not intended for short-term use, but rather for the ongoing management of chronic conditions like high blood pressure and angina.

How should Amlodipino be stored and disposed of?

Storage and Disposal of Amlodipine

The storage and disposal of amlodipine must strictly follow regulatory guidance to ensure product stability and safety.

Storage Requirements

Amlodipine tablets require storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be preserved in its original container to protect it from light and moisture and should be kept from freezing. All forms must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused amlodipine product must be disposed of according to local regulatory requirements for pharmaceutical waste. It is officially stated not to dispose of this medicine via wastewater or common household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlodipino found in:

A-Z Index: